AbCellera Biologics (STU:8QQ) EV-to-EBIT : -2.38 (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AbCellera Biologics's Enterprise Value is €469.02 Mil. AbCellera Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-196.95 Mil. Therefore, AbCellera Biologics's EV-to-EBIT for today is -2.38.

The historical rank and industry rank for AbCellera Biologics's EV-to-EBIT or its related term are showing as below:

STU:8QQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.73 Med: 7.69 Max: 3980.28
Current: -2.38

During the past 6 years, the highest EV-to-EBIT of AbCellera Biologics was 3980.28. The lowest was -22.73. And the median was 7.69.

STU:8QQ's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs STU:8QQ: -2.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AbCellera Biologics's Enterprise Value for the quarter that ended in Mar. 2024 was €650.82 Mil. AbCellera Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-196.95 Mil. AbCellera Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -30.26%.

AbCellera Biologics EV-to-EBIT Historical Data

The historical data trend for AbCellera Biologics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics EV-to-EBIT Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

62.40

15.18

9.26

-4.38

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-22.63	-10.92	-3.20	-4.38	-3.31

Competitive Comparison of AbCellera Biologics's EV-to-EBIT

For the Biotechnology subindustry, AbCellera Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's EV-to-EBIT falls into.

AbCellera Biologics EV-to-EBIT Calculation

AbCellera Biologics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	469.016	/	-196.954
	=	-2.38

AbCellera Biologics's current Enterprise Value is €469.02 Mil.
AbCellera Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-196.95 Mil.

AbCellera Biologics (STU:8QQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AbCellera Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-196.954	/	650.820433
	=	-30.26 %

AbCellera Biologics's Enterprise Value for the quarter that ended in Mar. 2024 was €650.82 Mil.
AbCellera Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-196.95 Mil.

AbCellera Biologics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (STU:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ABCL:USA

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines